In a nutshell The authors looked at the outcomes for patients with non-Hodgkin lymphoma (NHL) who have undergone allogeneic stem cell transplantation. The study concluded that even patients with aggressive NHL should consider allogeneic stem cell transplantation. Some background There are mutliple subtypes of non-Hodgkin lymphoma (NHL). Some...
Read More
In a nutshell This paper studied the effects of daratumumab in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Daratumumab in combination with bortezomib and dexamethasone led to a longer survival period without worsening disease. Some background Multiple myeloma is a cancer of...
Read MoreIn a nutshell This study examined the effect of new treatments for patients who have relapsed after an autologous stem cell transplantation. The authors concluded that patients treated with new therapies, including brentuximab vedotin (Adcetris), have significantly better outcomes. Some background Hodgkin lymphoma (HL) is generally...
Read More
In a nutshell This study examined the safety of combining a biologic therapy (pomalidomide [Pomalyst]), a targeted therapy (carfilzomib [Kyprolis]), and a steroid drug (dexamethasone [Decadron]) for relapsed or refractory multiple myeloma. Researchers reported early results on the safety and potential effectiveness of this treatment combination. Some...
Read MoreIn a nutshell The aim of this trial is to determine the effectiveness of a combination of the chemotherapies docetaxel (Taxotere) and carboplatin (Paraplatin) in advanced (spread beyond the prostate) prostate cancer. The main outcome to be measured is the number of patients who experience a decrease of 50% in prostate specific...
Read More
In a nutshell This study examined the safety and effectiveness of elotuzumab (Empliciti) for relapsed multiple myeloma. Researchers concluded that elotuzumab combined with lenalidomide (Revlimid) and dexamethasone was safe and effective at improving treatment outcomes for relapsed multiple myeloma. Some background Standard...
Read More
In a nutshell The authors examined haploidentical (matched donor) stem cell transplantation (haplo-SCT) as a treatment for patients who relapsed after autologous stem cell transplantation. The study concluded that haplo-SCT is a valid treatment for patients with relapsed Hodgkin lymphoma. Some background Most cases of Hodgkin lymphoma (HL) can be...
Read More
In a nutshell This study examined the outcomes for patients who received brentuximab vedotin before allogenic stem cell transplantation. The authors concluded that patients treated with brentuximab vedotin had generally good outcomes. Some background Hodgkin lymphoma (HL) is generally considered a curable disease. However, some patients will not...
Read More
In a nutshell The authors looked at several risk factors that may be associated with relapse after autologous stem cell transplantation (ASCT). The authors found that 5 risk factors were independently associated with relapse after ASCT: stage IV cancer before ASCT; less than 3 months between previous treatment and relapse; performance status of 1 or...
Read More
In a nutshell This phase 2 trial aims to test the safety and effectiveness of a combined treatment with ibrutinib (Imbruvica) and brentuximab vedotin (Adcetris) in recurrent (when the cancer comes back) Hodgkin lymphoma patients or in those who did not respond to the first line of treatment. This trial is recruiting in California, United...
Read More
In a nutshell This study investigated how effective and safe radium 223 dichloride treatment was in patients with castration resistant prostate cancer (CRPC). It was concluded that radium 223 dichloride increased overall survival, reduced symptomatic skeletal events risk and was safe. Some background Treatment to decrease the male hormones,...
Read More
In a nutshell The aim of this study was to determine whether the neutrophil to lymphocyte ratio (NLR) can be used to determine outcome in CRPC patients treated with enzalutamide (Xtandi). It was concluded that NLR could be used to predict the outcome for CRPC patients treated with enzalutamide. Some background Treatment for metastatic...
Read More
